Dental Research Journal, 2012 Background: Osteoclastogenesis is coordinated by the interaction of three members of the tumor necrosis factor (TNF) superfamily: Osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL)/receptor activator of nuclear factor kappa
Fatemeh Sarlati +3 more
doaj +4 more sources
Peroxiredoxin 1-Toll-like receptor 4-p65 axis inhibits receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation [PDF]
iScienceSummary: Peroxiredoxin 1 (PRDX1), an intracellular antioxidant enzyme, has emerged as a regulator of inflammatory responses via Toll-like receptor 4 (TLR4) signaling.
Jisu Park +8 more
doaj +2 more sources
Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors
Tohoku Journal of Experimental Medicine, 2019 Bone and soft tissue tumors are derived from mesenchymal cells, and they are hard to treat. Receptor-activator of nuclear factor-kappa B ligand (RANKL) is an essential cytokine for osteoclast differentiation and activation and is expressed on the surface of osteoblasts or stromal cells. In this study, to explore the potential of denosumab treatment for
Hiroshi Hatano +2 more
exaly +4 more sources
Receptor activator of nuclear factor kappa-B gene polymorphisms in Iranian periodontitis and peri-implantitis patients. [PDF]
J Periodontal Implant Sci, 2014 Peri-implantitis and periodontitis are inflammatory and infectious diseases of implant and tooth-supporting tissues. Recently, the role of gene polymorphisms of immune response components in the relevant pathogenesis has been investigated. The present study was the first to evaluate the relationship between two known single nucleotide polymorphisms ...
Kadkhodazadeh M +4 more
europepmc +4 more sources
Clinical Interventions in Aging, 2010 Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation.
Anne-Priscille Trouvin +1 more
doaj +2 more sources
Antibodies to receptor activator of nuclear factor-kappa B ligand (RANKL)
, 2008 Patent WO02095012A1 claims for the development of antibodies against receptor activator of nuclear factor-kappa B ligand (RANKL) and immunologically functional fragments that neutralize RANKL. These molecules can be used to detect RANKL in biological samples, allowing the identification of pathological conditions in which RANKL alteration contributes ...
Terpos, Evangelos +3 more
core +6 more sources
Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin‐Deficient Mice
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background The biological mechanism of action for osteoprotegerin, a soluble decoy receptor for the receptor activator of nuclear factor‐kappa B ligand in the vascular structure, has not been elucidated.
Toshihiro Tsuruda +12 more
doaj +1 more source
Exploring new pathways in endocrine-resistant breast cancer
Exploration of Targeted Anti-tumor Therapy, 2022 The most common breast cancer (BC) subtypes are hormone-dependent, being either estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or both, and altogether comprise the luminal subtype.
Inês Soares de Pinho +6 more
doaj +1 more source
Effect of lipopolysaccharide derived from surabaya isolates of Actinobacillus actinomycetemcomitans on alveolar bone destruction [PDF]
Veterinary World, 2018 Background: Actinobacillus actinomycetemcomitans' lipopolysaccharide (LPS) has a high virulence factor. It interacts with serum protein through receptors on the epithelial cell surface, thereby increasing both interleukin (IL)-1β, and IL-6 which results ...
Rini Devijanti Ridwan +3 more
doaj +1 more source
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis [PDF]
Clinical Rheumatology, 2017 Heidi Kokkonen +2 more
exaly +2 more sources